ABOUT DAISOGEL
SUPPORT
SEMINAR
With the rapid growth of GLP-1 peptides, new manufacturers are facing unexpected challenges. Despite being synthetically produced, GLP-1 peptides are highly prone to aggregation and fibrillation. These aggregates quickly compromise purification columns, demanding aggressive Cleaning In Place (CIP) protocols. We can help you understand the root causes of these challenges and implement effective solutions. Request an in-house seminar to learn from our team of specialists.
CONSULTING
Our research has revealed a critical insight: even identical synthetic GLP-1 molecules can possess different impurity profiles depending on the synthetic route used. Because of this, a “one-size-fits-all” approach to silica selection does not apply. We can quickly screen your crude peptide API to identify the exact silica phase required for your specific process.
TECHNICAL INFORMATION
Your knowledgebase for DAISOGEL silica gel products
REGULATRY SUPPORT
We have FDA DMF registration for the following phases:
- File# 23227 for Daisogel ODS series
- File# 22317 for Daisogel C8 series
- File# 29201 for Daisogel C4 series
We also have Regulatory Support Files for the same products available upon request.